434 related articles for article (PubMed ID: 30564303)
1. Tumour treating fields in a combinational therapeutic approach.
Branter J; Basu S; Smith S
Oncotarget; 2018 Nov; 9(93):36631-36644. PubMed ID: 30564303
[TBL] [Abstract][Full Text] [Related]
2. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.
Mun EJ; Babiker HM; Weinberg U; Kirson ED; Von Hoff DD
Clin Cancer Res; 2018 Jan; 24(2):266-275. PubMed ID: 28765323
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
5. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Mehta M; Wen P; Nishikawa R; Reardon D; Peters K
Crit Rev Oncol Hematol; 2017 Mar; 111():60-65. PubMed ID: 28259296
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Saria MG; Kesari S
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388
[TBL] [Abstract][Full Text] [Related]
7. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
8. Tumor treating fields: a new standard treatment for glioblastoma?
Taillibert S; Le Rhun E; Chamberlain MC
Curr Opin Neurol; 2015 Dec; 28(6):659-64. PubMed ID: 26551239
[TBL] [Abstract][Full Text] [Related]
9. Tumor treating fields with radiation for glioblastoma: a narrative review.
Miller R; Niazi M; Russial O; Poiset S; Shi W
Chin Clin Oncol; 2022 Oct; 11(5):40. PubMed ID: 36336899
[TBL] [Abstract][Full Text] [Related]
10. Tumour treating fields therapy for glioblastoma: current advances and future directions.
Rominiyi O; Vanderlinden A; Clenton SJ; Bridgewater C; Al-Tamimi Y; Collis SJ
Br J Cancer; 2021 Feb; 124(4):697-709. PubMed ID: 33144698
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
12. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Schwartz MA; Onuselogu L
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
[TBL] [Abstract][Full Text] [Related]
13. First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.
Kassubek R; Mathieu R
Brain Sci; 2022 Apr; 12(4):. PubMed ID: 35448029
[TBL] [Abstract][Full Text] [Related]
14. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
15. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
[TBL] [Abstract][Full Text] [Related]
16. Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Wong ET; Lok E; Swanson KD
Prog Neurol Surg; 2018; 32():180-195. PubMed ID: 29990984
[TBL] [Abstract][Full Text] [Related]
17. Alternating Electric Fields (TTFields) Activate Ca
Neuhaus E; Zirjacks L; Ganser K; Klumpp L; Schüler U; Zips D; Eckert F; Huber SM
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669316
[TBL] [Abstract][Full Text] [Related]
18. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.
Lacouture ME; Anadkat MJ; Ballo MT; Iwamoto F; Jeyapalan SA; La Rocca RV; Schwartz M; Serventi JN; Glas M
Front Oncol; 2020; 10():1045. PubMed ID: 32850308
[No Abstract] [Full Text] [Related]
19. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
20. Skin toxicities associated with tumor treating fields: case based review.
Lukas RV; Ratermann KL; Wong ET; Villano JL
J Neurooncol; 2017 Dec; 135(3):593-599. PubMed ID: 28849343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
